UPneeq

Feel like you have droopy eyelids?

BLEPHAROPTOSIS (LOW-LYING LIDS)

A common eyelid disorder that can impact adults of all ages, not just those over age 50.

  • Can make eyes appear tired/sleepy/droopy, or make one eyelid visibly lower than the other
  • May cause vision impairment, interfering with day-to-day functions (reading, driving, computer use)

Meet Upneeq® (oxymetazoline hydrochloride ophthalmic solution), 0.1%. The only FDA-approved once-daily prescription eyedrop for acquired ptosis in adults that lifts your upper eyelids.

Schedule an appointment to find out if Upneeq is right for you. You'll have the option to book an in office or virtual consultation with Dr. Sheena Garner OD

The one time consultation fee is $75 dollars. You will get samples at your appointment. If you are in a different city, we will send complimentary samples after your virtual visit with Dr. Garner. If you are outside the United States we are unable to offer samples due to shipping cost. 

Orders can be placed right away or we can send you a link to pay when you are ready. Once again shipping is free only within the United States.

The price of UPneeq is $150 for 30 vials and $375 for 90 vials. Each vial has four drops which will be enough for two uses. 

The full effect of the drop is acquired after 2 hours and will last up to 8 hours. 

WARNINGS AND PRECAUTIONS

  • Ptosis may be associated with neurologic or orbital diseases such as stroke and/or cerebral aneurysm, Horner syndrome, myasthenia gravis, external ophthalmoplegia, orbital infection and orbital masses. Consideration should be given to these conditions in the presence of ptosis with decreased levator muscle function and/or other neurologic signs.
  • Alpha-adrenergic agonists as a class may impact blood pressure. Advise UPNEEQ patients with cardiovascular disease, orthostatic hypotension, and/or uncontrolled hypertension or hypotension to seek medical care if their condition worsens.
  • Use UPNEEQ with caution in patients with cerebral or coronary insufficiency or Sjögren’s syndrome. Advise patients to seek medical care if signs and symptoms of potentiation of vascular insufficiency develop.
  • UPNEEQ may increase the risk of angle closure glaucoma in patients with untreated narrow-angle glaucoma. Advise patients to seek immediate medical care if signs and symptoms of acute narrow-angle glaucoma develop.
  • Patients should not touch the tip of the single patient-use container to their eye or to any surface, in order to avoid eye injury or contamination of the solution.

ADVERSE REACTIONS

Adverse reactions that occurred in 1-5% of subjects treated with UPNEEQ were punctate keratitis, conjunctival hyperemia, dry eye, blurred vision, instillation site pain, eye irritation and headache.

DRUG INTERACTIONS

  • Alpha-adrenergic agonists, as a class, may impact blood pressure. Caution in using drugs such as beta blockers, anti-hypertensives, and/or cardiac glycosides is advised. Caution should also be exercised in patients receiving alpha adrenergic receptor antagonists such as in the treatment of cardiovascular disease, or benign prostatic hypertrophy.
  • Caution is advised in patients taking monoamine oxidase inhibitors which can affect the metabolism and uptake of circulating amines.

To report SUSPECTED ADVERSE REACTIONS or product complaints, contact RVL Pharmaceuticals at 1-877-482-3788. You may also report SUSPECTED ADVERSE REACTIONS to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.